Related Articles
18 April 2023
NeoPhore Limited, a small molecule neoantigen immuno-oncology
company, today announces that it has signed a strategic collaboration agreement with Professor Chris
Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s
proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent
activity against tumours with defined genetic backgrounds.
19 January 2023
9 March 2021
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
Get in touch
Thank you for your form submission, we will get in contact with you shortly.
